Core Viewpoint - Quantum BioPharma Ltd. has made a strategic investment by purchasing 2,000 shares of GameStop Corp. to enhance shareholder value and combat market corruption [1][4]. Group 1: Strategic Investments - The acquisition of GameStop shares is part of Quantum BioPharma's strategy to deploy capital towards undervalued assets with strong fundamentals [4]. - Kevin Malone, Board Advisor, highlighted the value in GameStop, noting that the company holds 90% cash and marketable securities on its balance sheet [5]. Group 2: Advocacy Against Market Manipulation - Quantum BioPharma has appointed advocates like Kevin Malone and Terry Lynch to combat market corruption, particularly against naked short selling and stock manipulation [2]. - The company has filed an amended complaint seeking damages exceeding $700 million against CIBC World Markets and RBC Dominion Securities for alleged stock price manipulation through spoofing techniques [3]. Group 3: Shareholder Value Initiatives - The company is advancing its Multiple Sclerosis Patented New Chemical Entity asset and intends to declare a special dividend tied to potential litigation settlements [4]. - Quantum BioPharma has completed a debt settlement by issuing Class B shares, further demonstrating its commitment to prudent financial management [6]. Group 4: Company Overview - Quantum BioPharma is focused on developing innovative therapies for neurodegenerative disorders, with its lead compound, Lucid-MS, aimed at preventing myelin degradation in multiple sclerosis [8]. - The company retains a 20.11% ownership stake in Unbuzzd Wellness Inc. and has a royalty agreement for sales from its product unbuzzd™ [8].

Core Insights - Quantum BioPharma Ltd. has submitted its patented drug candidate Lucid-21-302 (Lucid-MS) for the Innovative Licensing and Access Pathway (ILAP) Passport program in the UK, aiming to provide a new treatment for multiple sclerosis (MS) [1][3] Group 1: Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, with drug candidates at various development stages [4] - The company’s lead compound, Lucid-MS, is a patented new chemical entity that has shown potential in preventing and reversing myelin degradation in preclinical models [4] - Quantum BioPharma retains a 20.11% ownership stake in Unbuzzd Wellness Inc. and has a royalty agreement that includes 7% of sales until total payments reach $250 million, after which the royalty will drop to 3% [4] Group 2: ILAP Passport Program - The ILAP Passport is designed to expedite the development and delivery of groundbreaking medicines by fostering collaboration among medicine developers, regulatory bodies, and the NHS [2] - The program aims to streamline the process of developing, reviewing, approving, and delivering new treatments to patients, ensuring timely access to medical innovations [2] Group 3: Statements from Company Executives - Dr. Andrzej Chruscinski expressed excitement about the ILAP Passport submission, highlighting its potential to accelerate clinical development and patient access to Lucid-21-302 [3] - Dr. Lakshmi P. Kotra emphasized the company's commitment to bringing innovative drugs to patients quickly and the importance of global regulatory strategies [4]

Core Viewpoint - Quantum BioPharma Ltd. is completing a non-brokered private placement of class A multiple voting shares at a price of $50 per share, aiming for gross proceeds of up to $600 million, expected to be fully subscribed by existing holders of MVS [1][3]. Group 1: Offering Details - The Offering consists of class A multiple voting shares priced at $50 each, with total gross proceeds anticipated to reach $600 million [1]. - All securities issued in the Offering are subject to a statutory hold period of four months plus a day from issuance, in accordance with Canadian securities laws [2]. - The proceeds from the Offering will be utilized for general working capital purposes [2]. Group 2: Insider Participation - The Offering is expected to be fully subscribed by Xorax Family Trust and Fortius Research and Trading Corp., both of which have insider connections to the Company [3]. - The participation of these insiders is classified as a "related-party transaction" under Multilateral Instrument 61-101, with exemptions from formal valuation and minority shareholder approval requirements being relied upon [3]. Group 3: Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, with drug candidates at various development stages [6]. - The Company’s lead compound, Lucid-MS, is designed to prevent and reverse myelin degradation, a key factor in multiple sclerosis, and is currently in preclinical models [6]. - Quantum BioPharma retains a 20.11% ownership stake in Unbuzzd Wellness Inc. and is entitled to royalty payments of 7% on sales until reaching $250 million, after which the royalty rate will decrease to 3% [6].

Core Insights - Quantum BioPharma Ltd. has engaged MZ Digital and Dealmaker to raise up to US$5 million through a Regulation D 506(c) offering for Unbuzzd Wellness Inc., which produces a beverage that accelerates alcohol metabolism and reduces hangover symptoms [1][2] Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, including alcohol misuse disorders [3] - Unbuzzd Wellness Inc. is a public issuer that offers a scientifically backed beverage designed to help alcohol consumers manage their consumption and recovery [5] Product Details - Unbuzzd is a proprietary blend of vitamins, minerals, and herbs that aids in faster alcohol metabolism, restores mental clarity, and improves cognition [5] - Clinical trials have shown that unbuzzd reduces blood alcohol concentration (BAC) by over 40% faster within 30 minutes compared to control subjects, with significant improvements in alertness and reduced hangover symptoms [6][7][14] Financial Aspects - Quantum BioPharma retains a 20.11% ownership stake in Unbuzzd Wellness Inc. and is entitled to 7% royalty payments on sales until reaching $250 million, after which the royalty rate drops to 3% [3]

Core Viewpoint - Quantum BioPharma Ltd. announces that Unbuzzd Wellness Inc. is raising up to US$5 million through a Regulation D 506(c) offering to support its expansion plans for the unbuzzd™ beverage, which accelerates alcohol metabolism and reduces hangover symptoms [1][2][3] Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, including alcohol misuse disorders [3] - The company retains a 20.11% ownership stake in Unbuzzd Wellness Inc. and is entitled to 7% royalty payments on unbuzzd™ sales until reaching $250 million, after which the royalty rate drops to 3% [3] Product Details - Unbuzzd™ is a scientifically-backed beverage designed to help alcohol consumers process alcohol faster, restore mental clarity, and alleviate hangover symptoms [5][6] - Clinical trials show that unbuzzd accelerates alcohol metabolism, reducing blood alcohol concentration (BAC) by over 40% faster within 30 minutes compared to control subjects [6][13] - Participants reported significant improvements in alertness and reductions in hangover symptoms, including a 67% reduction in headache severity at four hours post-consumption [13] Leadership and Strategy - John Duffy, CEO of Unbuzzd, emphasizes the commitment to providing a scientifically backed product to alcohol consumers and the importance of the capital raise for expansion [2] - Gerry David, Board Co-Chair, highlights that the capital raise will support company growth and position unbuzzd for a potential initial public offering [3]

Core Insights - Quantum BioPharma Ltd. is making significant advancements in its clinical pipeline, particularly with its FSD202 program targeting nociplastic pain in patients with Idiopathic Mast Cell Activation Syndrome (MCAS) and its Lucid-MS program for progressive Multiple Sclerosis [2][3] Clinical Development Milestones - The FSD202 program has received HREC approval for a Phase 2 clinical trial, enrolling 60 patients to assess pain reduction over 28 days [2] - The Lucid-MS program is expected to file an IND application with the U.S. FDA in Q4 2025, which would allow progression to Phase 2 trials [3] Strategic Business Developments - The subsidiary Celly Nutrition has rebranded to Unbuzzd Wellness Inc. and is preparing for a potential IPO to enhance capital for marketing its alcohol metabolism product [4] - Quantum BioPharma holds a 20.11% stake in Unbuzzd Wellness, positioning it to benefit from the subsidiary's growth [4] Financial Performance - For Q1 2025, Quantum BioPharma reported no revenues, with general and administrative expenses down 31% to $1.32 million, while R&D expenses rose to $1.65 million [6][7] - The company maintained cash and cash equivalents of $3.5 million as of March 31, 2025, ensuring liquidity through Q1 2027 [7] Pipeline Overview - The company's pipeline includes Lucid-MS for progressive Multiple Sclerosis, FSD202 for MCAS and inflammatory diseases, and unbuzzd™ for alcohol metabolism [8] Investment Strategy - Quantum BioPharma has diversified its treasury holdings towards Bitcoin, with total investments reaching $5 million [5] - The company plans to issue special dividends linked to potential litigation proceeds exceeding $700 million related to alleged stock manipulation [5]

Core Insights - Quantum BioPharma Ltd. has initiated a joint clinical study with Massachusetts General Hospital to validate a novel PET imaging technique for monitoring myelin integrity in multiple sclerosis (MS) patients [1][2] - The study utilizes the PET tracer [F]3F4AP, which has shown high sensitivity to demyelinated lesions and favorable pharmacokinetics in previous studies, indicating its potential as a biomarker for monitoring demyelination [1][3] - The new combined GE Signa PET-MR scanner at MGH enhances the imaging process by allowing simultaneous acquisition of PET and MRI signals, improving the accuracy of monitoring demyelination over time [2][3] Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, with a lead compound, Lucid-MS, aimed at preventing and reversing myelin degradation in MS [4] - The company retains a 20.11% ownership stake in Unbuzzd Wellness Inc. and has a royalty agreement that includes 7% of sales until total payments reach $250 million, after which the royalty rate drops to 3% [4] - Quantum BioPharma also maintains a portfolio of strategic investments through its subsidiary, FSD Strategic Investments Inc., which includes loans secured by residential or commercial property [4]

Core Viewpoint - Quantum BioPharma Ltd. intends to declare a special dividend consisting of Contingent Value Rights (CVRs) to holders of its Class B Subordinate Voting Shares, reflecting the company's commitment to its shareholders [1][3]. Group 1: Special Dividend and CVRs - Each CVR will entitle holders to receive a pro rata portion of a minimum of 10% and a maximum of 50% of the net proceeds from the company's legal action against certain banks, seeking damages exceeding USD 700 million for alleged stock price manipulation [2][8]. - The exact payout percentage for the CVRs will be approved by the Board at a later date [2][3]. - The record date for the proposed special dividend has not yet been established, and further updates will be provided [3]. Group 2: Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, with drug candidates at various development stages [4]. - The company’s lead compound, Lucid-MS, aims to prevent and reverse myelin degradation, a key factor in multiple sclerosis, and is currently in preclinical models [4][8]. - Quantum BioPharma retains a 20.11% ownership stake in Unbuzzd Wellness Inc. and has a royalty agreement that includes 7% of sales until total payments reach USD 250 million, after which the royalty will drop to 3% [4]. Group 3: Legal and Regulatory Considerations - The issuance of the CVRs is subject to necessary approvals, regulatory requirements, and finalization of tax, legal, and operational matters [3][8]. - There is no assurance that any proceeds from the litigation will be received or that the CVRs will result in any payment to holders [3][7].

Core Viewpoint - Quantum BioPharma Ltd. has purchased an additional USD $5,000,000 worth of Bitcoin and other cryptocurrencies as part of its strategic efforts to enhance shareholder returns and hedge against the dollar [1][2]. Group 1: Cryptocurrency Investment - The total amount of Bitcoin and other cryptocurrencies held by the company now stands at USD $5,000,000 [1]. - The company believes in the potential of cryptocurrencies to provide returns on investment for shareholders [2]. - Quantum BioPharma is set up to receive financing and conduct transactions in cryptocurrencies [2]. Group 2: Compliance and Custodianship - All cryptocurrency holdings are managed by a fully compliant custodian, ensuring adherence to financial and audit regulations [3]. - The company will continue to monitor market conditions and may adjust its cryptocurrency holdings as deemed appropriate [3]. Group 3: Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders [4]. - The company retains a 20.11% ownership stake in Celly Nutrition Corp., which includes a royalty agreement of 7% on sales from its product unbuzzd™ until total payments reach USD $250 million [4]. - Quantum BioPharma maintains a portfolio of strategic investments through its subsidiary, FSD Strategic Investments Inc., which includes loans secured by residential or commercial property [4].

Core Viewpoint - Quantum BioPharma Ltd. addresses misinformation regarding its name and potential reverse takeover with Unbuzzd Wellness Inc., clarifying that it has not changed its name and is not involved in any RTO transaction with Unbuzzd [1][2] Company Overview - Quantum BioPharma is a biopharmaceutical company focused on innovative assets and biotech solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders [6] - The company retains a 20.11% ownership stake in Unbuzzd Wellness Inc. as of March 31, 2025, and has developed the product unbuzzd™, which aids in alcohol metabolism [6] Financial Agreements - Quantum BioPharma is the largest shareholder and debt holder of Unbuzzd Wellness Inc., receiving a 7% royalty on revenue until a total of $250 million is paid, after which the rate drops to 3% [3] - Quantum BioPharma has issued 200 million common shares to Unbuzzd Wellness Inc. as a license fee and holds an anti-dilution warrant to increase its stake to 25% [3] - A loan agreement was established where Quantum loaned Unbuzzd Wellness Inc. $1.3 million at a 10% annual interest rate, secured for three years [3] Leadership and Expertise - Unbuzzd Wellness Inc. is led by CEO John Duffy, who has a strong background in the beverage industry, and is supported by Gerry David, former CEO of Celsius Holdings, Inc. [4] Product Information - Unbuzzd is a scientifically-backed product that accelerates alcohol metabolism and reduces hangover symptoms, supported by clinical trials [9] - The product is available in various formats and aims to appeal to consumers looking for responsible drinking solutions [8][9] Debt Settlement - Quantum BioPharma has authorized a debt settlement totaling USD $20,930 with Class B Shares, expected to be completed in early June 2025 [5]